Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $42.26 USD
Change Today +0.12 / 0.28%
Volume 2.1M
GSK On Other Exchanges
New York
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSK) Key Developments

GSK Invests in Antibiotic Manufacturing Facility in Singapore

GlaxoSmithKline plans to invest another GBP 38 million into its antibiotic manufacturing plant in Singapore. The increase in investment comes in addition to GSK's original investment of SGD 60 million in 2012. GSK expects the latest investment to boost the plant's production by 50%.

GlaxoSmithKline Updates on BEXSERO

GlaxoSmithKline announced that the U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination, including BEXSERO® (Meningococcal Group B Vaccine), in individuals aged 16 to 23 (with a preferred age of 16-18). This recommendation means that the decision to vaccinate against meningococcal group B will be made by qualified healthcare professionals, based on individual patient risk assessment. BEXSERO® was approved by the U.S. Food and Drug Administration (FDA) in January 2015 through an accelerated approval pathway for use in individuals aged 10 through 25 years and acquired by GSK in March 2015 following the closure of the three-part transaction with Novartis. During meeting on June 24, 2015, the ACIP also voted to include BEXSERO® in the CDC's Vaccines for Children (VFC) program for ages 16 through 18. The ACIP voted in February for the use of meningococcal group B vaccines in people greater than 10 years of age at increased risk for meningococcal group B disease and this was published on June 12, 2015. GSK is evaluating the safety and immune response of a pentavalent meningococcal vaccine (A, C, W-135, Y, plus B) which is now in Phase 2 research. GSK plans to continue to invest in vaccines against this disease as a key part of its growth strategy.

GlaxoSmithKline (UK) Announces Launch of US-Based Altius Institute for Biomedical Sciences; Appoints John A Stamatoyannopoulos to Lead the Altius Institute for Biomedical Sciences

GlaxoSmithKline (UK) has announced the launch of an independent non-profit research institute - the Altius Institute for Biomedical Sciences - based in Seattle, Washington. GSK signed a 10-year research agreement with Altius, whereby the firm will contribute more than USD 95 million in the first five years to help fund research activities that are also anticipated to receive funding from public and other sources. Furthermore, undisclosed additional funding will be provided by GSK for certain drug discovery and development projects selected by the firm. The institute will be led by John A Stamatoyannopoulos, professor of Genome Sciences and Medicine at the University of Washington School of Medicine, and will be focused on developing new technologies for identification of genes involved in controlling a cell's operating functions during the states of health and disease. Altius is anticipated to become operational later in 2015.

GlaxoSmithKline Announces Executive Changes

GlaxoSmithKline has named Annaswamy Vaidheesh as its new vice president for South Asia division and managing director of the firm. Vaidheesh would succeed current managing director Hasit Joshipura, who is expected to be appointed on a new role in the company. Prior to his new role, Vaidheesh was working as vice president of corporate government affairs at Johnson & Johnson Asia-Pacific headquartered in Singapore. He also served as managing director at Johnson & Johnson Medical India and also remained vice president at Diabetes' Asia-Pacific franchise in Mumbai.

Glaxosmithkline Sells Meningitis Vaccines to Pfizer

GlaxoSmthKline plc plans to sell meningitis vaccines Nimenrix and Mencevaz to Pfizer Inc. (PFE) for EUR 115 million. The divestment addresses commitments GlaxoSmithKline made to regulators at the European Commission and elsewhere in connection with its three-pronged transaction with Novartis AG, which closed in March. The deal included the EUR 5.25 billion purchase of most of Novartis' vaccines unit, including meningitis products Menveo and Bexsero, as well as the formation of a consumer healthcare joint venture and the EUR 16 billion sale to Novartis of GlaxoSmithKline's oncology division. The two vaccines the U.K. company is selling to Pfizer are available outside the U.S. They had sales in 2014 of EUR 34 million. The EC and other regulators need to clear the deal, which counts as a related-party transaction since Pfizer is GlaxoSmithKline's partner in the ViiV Healthcare Ltd. HIV drugs venture. A Ropes & Gray LLP team led by Christopher Comeau and Mark Bellomy provided legal counsel to Pfizer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $42.26 USD +0.12

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $155.38 USD -0.27
AbbVie Inc $68.21 USD -0.30
Celgene Corp $119.52 USD +1.30
Eli Lilly & Co $86.14 USD +1.29
Medtronic PLC $73.81 USD -0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation GSK Industry Range
Price/Earnings 6.8x
Price/Sales 3.0x
Price/Book 9.2x
Price/Cash Flow 6.8x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at